Cognitive Tests for People With Huntington's Disease
Studies two thinking-skill tests in adults living with Huntington's disease.
Plain-language title generated from the registry record
Registry title: Cognitive Assessment Tools for Huntington's Disease.
Key facts
- Where
- Columbus, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Source: NCT06546488, who can take part
Where in United States
- The Ohio State University -Wexner Medical CenterColumbus, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ohio State University
- Trial code
- NCT06546488
- Record updated
- 2 March 2026
- Original description
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.Read full original descriptionShow less
Cognitive Assessment Tools for Individuals With Huntington's Disease.
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.
Inclusion: Males and females aged 30-65 (inclusive) at the time of signing the informed consent form; Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40; A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4; Vision and hearing sufficient for compliance with tests; On a stable dose of medications for 30 days prior to the time of signing the informed consent form.
Exclusion: Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant; Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure); Subjects with a history of a learning disability; Age of symptom onset less than 19 years old or greater than 60 years old; Subjects who are pregnant or breast feeding; Subjects who are unable to provide consent.